Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis.
OBJECTIVE
To report on 2 cases of metastatic renal cell cancer treated with sunitinib during chronic hemodialysis.


METHODS
Two patients who were receiving chronic hemodialysis were treated with escalating doses of sunitinib with close clinical and laboratory surveillance.


RESULTS
The treatment toxicities were tolerable even after dose escalation. The first patient had a complete response after 5 treatment cycles and the second patient had stable disease after 13 treatment cycles.


CONCLUSIONS
Sunitinib treatment is feasible and effective against metastatic renal cell cancer with the patient receiving chronic hemodialysis. Patients with terminal renal failure can be offered sunitinib treatment with close clinical and laboratory monitoring.
Zastrow
Stefan
S
Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany. stefan.zastrow@uniklinikum-dresden.de
Froehner
Michael
M
Platzek
Ivan
I
Novotny
Vladimir
V
Wirth
Manfred P
MP
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D011758:Pyrroles / Q000627:therapeutic use*; D006435:Renal Dialysis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib